Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767573 | 0.99 | DRD2 (0.39) | DRD2ADRA1BADRA1AHTR1AADRA1D | |
| SCHEMBL2766431 | 0.96 | ADRA1B (0.38) | DRD2ADRA1BADRA1AHTR1AADRA1D | |
| SCHEMBL2767124 | 0.92 | DRD2 (0.42) | DRD2ADRA1BADRA1AHTR1AADRA1D | |
| SCHEMBL2768088 | 0.87 | SLC18A3 (0.38) | SIGMAR1 | |
| SCHEMBL2766482 | 0.82 | FFAR4 (0.47) | DRD2ADRA1AHTR1ADRD3SIGMAR1 | |
| SCHEMBL2766690 | 0.81 | DRD2 (0.42) | DRD2DRD3HTR2AHTR2CHTR7 | |
| Hydrochloric Acid SCHEMBL2766446 | 0.81 | DRD2 (0.41) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL2767200 | 0.81 | FFAR4 (0.47) | DRD2ADRA1AHTR1ADRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2767977 | 0.79 | SLC6A2 (0.41) | DRD2ADRA1BADRA1AHTR1AADRA1D | |
| SCHEMBL2766230 | 0.79 | DRD2 (0.46) | DRD2ADRA1AHTR1ADRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | DRD2 3225/4885ADRA1B 1233/4885ADRA1A 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.